m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02116)
Name
PWT-33597
Synonyms
PI3 kinase alpha/mTOR dual inhibitor (cancer), Pathway Therapeutics
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C26H30F2N8O4S
InChI
1S/C26H30F2N8O4S/c1-34(2)13-16-41(37,38)33-18-9-7-17(8-10-18)23-30-25(35-11-14-40-15-12-35)32-26(31-23)36-19-5-4-6-20(39-3)21(19)29-24(36)22(27)28/h4-10,22,33H,11-16H2,1-3H3
InChIKey
GDCJHDUWWAKBIW-UHFFFAOYSA-N
PubChem CID
46917355
TTD Drug ID
D0Y0FE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
PI3-kinase alpha (PIK3CA)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase alpha (PIK3CA) is a therapeutic target for PWT-33597. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PWT-33597 through regulating the expression of PI3-kinase alpha (PIK3CA). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase alpha (PIK3CA) is a therapeutic target for PWT-33597. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PWT-33597 through regulating the expression of PI3-kinase alpha (PIK3CA). [2], [3]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary PI3-kinase alpha (PIK3CA) is a therapeutic target for PWT-33597. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of PWT-33597 through regulating the expression of PI3-kinase alpha (PIK3CA). [2], [4]
Serine/threonine-protein kinase mTOR (mTOR)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). [5], [6]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). [6], [7]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). [6], [8]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). [6], [9]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Serine/threonine-protein kinase mTOR (mTOR) is a therapeutic target for PWT-33597. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of PWT-33597 through regulating the expression of Serine/threonine-protein kinase mTOR (mTOR). [5], [6]
References
Ref 1 METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner. Cancer Manag Res. 2020 Dec 23;12:13173-13184. doi: 10.2147/CMAR.S286275. eCollection 2020.
Ref 2 Adaptive resistance to PI3KAlpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 2021 Jan 14;12(1):85. doi: 10.1038/s41419-020-03370-4.
Ref 3 Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma - a retrospective study using TCGA database. Aging (Albany NY). 2019 Mar 15;11(6):1633-1647. doi: 10.18632/aging.101856.
Ref 4 ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2. J Exp Clin Cancer Res. 2019 Apr 15;38(1):163. doi: 10.1186/s13046-019-1159-2.
Ref 5 Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition. Theranostics. 2021 Jul 25;11(17):8464-8479. doi: 10.7150/thno.60028. eCollection 2021.
Ref 6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 7 The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway. J Clin Lab Anal. 2021 Mar;35(3):e23655. doi: 10.1002/jcla.23655. Epub 2020 Dec 12.
Ref 8 Methyltransferase-like 3 promotes the progression of lung cancer via activating PI3K/AKT/mTOR pathway. Clin Exp Pharmacol Physiol. 2022 Jul;49(7):748-758. doi: 10.1111/1440-1681.13647. Epub 2022 May 23.
Ref 9 YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition. Exp Hematol Oncol. 2021 Jun 4;10(1):35. doi: 10.1186/s40164-021-00227-0.